Miklós Egyed

944 total citations
23 papers, 171 citations indexed

About

Miklós Egyed is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Miklós Egyed has authored 23 papers receiving a total of 171 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 12 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Miklós Egyed's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Miklós Egyed is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Miklós Egyed collaborates with scholars based in Hungary, France and United States. Miklós Egyed's co-authors include Péter Reményi, Magdalena Koszarska, András Bors, Attila Tordai, Árpád Bátai, Tamás Masszi, Judit Csomor, Hajnalka Andrikovics, Ruben A. Mesa and Jean‐Jacques Kiladjian and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Pathology.

In The Last Decade

Miklós Egyed

18 papers receiving 170 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miklós Egyed Hungary 7 156 100 94 51 25 23 171
Benedetta Sordi Italy 4 140 0.9× 118 1.2× 78 0.8× 54 1.1× 10 0.4× 9 169
Pencho Georgiev Bulgaria 11 127 0.8× 230 2.3× 97 1.0× 49 1.0× 25 1.0× 30 333
Olivier Mansier France 7 109 0.7× 102 1.0× 80 0.9× 51 1.0× 7 0.3× 15 164
C Mannarelli Italy 3 240 1.5× 213 2.1× 157 1.7× 67 1.3× 12 0.5× 3 266
Rabia Shahswar Germany 6 120 0.8× 157 1.6× 68 0.7× 41 0.8× 10 0.4× 12 185
Faye Feller United States 7 97 0.6× 124 1.2× 110 1.2× 24 0.5× 6 0.2× 25 187
Blanka Kubešová Czechia 3 245 1.6× 191 1.9× 142 1.5× 88 1.7× 8 0.3× 6 257
Stefano Ulisciani Italy 4 45 0.3× 71 0.7× 40 0.4× 28 0.5× 13 0.5× 6 96
Denise Wolleschak Germany 9 86 0.6× 85 0.8× 84 0.9× 35 0.7× 5 0.2× 25 157
Lara Mannelli Italy 5 105 0.7× 80 0.8× 59 0.6× 40 0.8× 16 0.6× 14 123

Countries citing papers authored by Miklós Egyed

Since Specialization
Citations

This map shows the geographic impact of Miklós Egyed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miklós Egyed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miklós Egyed more than expected).

Fields of papers citing papers by Miklós Egyed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miklós Egyed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miklós Egyed. The network helps show where Miklós Egyed may publish in the future.

Co-authorship network of co-authors of Miklós Egyed

This figure shows the co-authorship network connecting the top 25 collaborators of Miklós Egyed. A scholar is included among the top collaborators of Miklós Egyed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miklós Egyed. Miklós Egyed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pinczés, László Imre, Botond Tímár, Márk Plander, et al.. (2025). Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy. The Journal of Pathology. 266(4-5). 395–404.
2.
Kiladjian, Jean‐Jacques, Alessandro M. Vannucchi, Aaron T. Gerds, et al.. (2023). Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials. HemaSphere. 7(11). e963–e963. 10 indexed citations
3.
Verstovšek, Srđan, Ruben A. Mesa, Vikas Gupta, et al.. (2023). Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Advances. 7(14). 3582–3591. 25 indexed citations
4.
Sharman, Jeff P., Miklós Egyed, Wojciech Jurczak, et al.. (2022). Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.. Journal of Clinical Oncology. 40(16_suppl). 7539–7539. 18 indexed citations
5.
Gerds, Aaron T., Srđan Verstovšek, Alessandro M. Vannucchi, et al.. (2022). Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].. Journal of Clinical Oncology. 40(16_suppl). 7061–7061. 5 indexed citations
6.
7.
Mesa, Ruben A., Srđan Verstovšek, Uwe Platzbecker, et al.. (2022). Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib. Blood. 140(Supplement 1). 3983–3985. 1 indexed citations
8.
9.
Egyed, Miklós, et al.. (2022). Klónok Háborúja – Egy CML-es betegben észlelt klonális evolúció. 55(2). 54–57.
10.
Oh, Stephen T., Srđan Verstovšek, Jason Gotlib, et al.. (2022). Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib. Blood. 140(Supplement 1). 821–823. 6 indexed citations
11.
Gerds, Aaron T., Ruben A. Mesa, Alessandro M. Vannucchi, et al.. (2022). Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor. Blood. 140(Supplement 1). 1514–1517. 4 indexed citations
12.
Verstovšek, Srđan, Ruben A. Mesa, Vikas Gupta, et al.. (2022). Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs). Blood. 140(Supplement 1). 9670–9672. 1 indexed citations
13.
Kiladjian, Jean‐Jacques, Christoph Klade, Pencho Georgiev, et al.. (2022). Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV). Blood. 140(Supplement 1). 9663–9664. 3 indexed citations
14.
15.
16.
Bajzik, Gábor, Miklós Egyed, Zsolt Vajda, et al.. (2018). A PET/MR képalkotás magyarországi klinikai alkalmazásának lehetőségei, első tapasztalatai. Orvosi Hetilap. 159(34). 1375–1384.
17.
Kajtár, Béla, Péter Rajnics, Miklós Egyed, & Hussain Alizadeh. (2015). Case report: Concomitant Chronic Lymphocytic Leukaemia and Cytogenetically Normal de novo Acute Leukaemia in a Patient.. PubMed. 45(5). 602–6. 2 indexed citations
18.
Andrikovics, Hajnalka, András Bors, Magdalena Koszarska, et al.. (2014). Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica. 99(7). 1184–1190. 63 indexed citations
19.
20.
Egyed, Miklós, et al.. (2007). Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy. Haematologica. 92(2). e26–e27. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benedetta Sordi Breakdown of academic impact, for papers by Pencho Georgiev Breakdown of academic impact, for papers by Olivier Mansier Breakdown of academic impact, for papers by C Mannarelli Breakdown of academic impact, for papers by Rabia Shahswar Breakdown of academic impact, for papers by Faye Feller Breakdown of academic impact, for papers by Blanka Kubešová Breakdown of academic impact, for papers by Stefano Ulisciani Breakdown of academic impact, for papers by Denise Wolleschak Breakdown of academic impact, for papers by Lara Mannelli
Rankless by CCL
2026